Crimson Publishers Publish With Us Reprints e-Books Video articles


Novel Approaches in Cancer Study

The Potential for Individualization of NeoadjuvantChemotherapy in Breast Cancer

  • Open or Close Hojouj Mohammad IM*

    Department of Oncology and Medical Radiology, Ukraine

    *Corresponding author: Hojouj Mohammad IM, Department of Oncology and Medical Radiology, VVernadskiiStreet, 9, Dnipro, 49044, Ukraine

Submission: April04, 2018;Published: August 09, 2018

DOI: 10.31031/NACS.2018.02.000526

Volume2 Issue1


The preoperative, or, as it is often called, neoadjuvant chemotherapy (NAPCT) of operable breast cancer (the breast cancer) with affected regional lymph nodes has in its time replaced preoperative radiotherapy, as it has a number of significant advantages over the latter. The most important advantage of NAPCT is its systemic action, which allows to “catching up” with probable distant micro-metastases or circulating tumor cells, while pre-operative radiotherapy has a local effect, and on the systemic level the tumor continues to develop. Despite of the fact that with operative breast cancer the time of NAPCT (before or after the operation) does not affect to the long-term results of treatment, the latter becomes applicable even for operable breast cancer without affected regional lymph nodes.According to the literature, NAPCT with primary-operative breast cancer allows: 1) make organ saving operations; 2) improve the prognosis in cases of complete morphological regression in patients with triple negative and Her2 / neu positive (non-luminal) subtypes; 3) evaluate the effect of chemotherapy and, in the absence of effect, stop it on time [1].

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137